1/14
08:05 am
scnx
SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment
Medium
Report
SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment
1/5
10:57 am
scnx
Pharma Contract Sales Market Report 2025-2035: CRO-CSO Integration Enhances Commercialisation Models [Yahoo! Finance]
Low
Report
Pharma Contract Sales Market Report 2025-2035: CRO-CSO Integration Enhances Commercialisation Models [Yahoo! Finance]
12/22
08:23 am
scnx
SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA [Yahoo! Finance]
High
Report
SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA [Yahoo! Finance]
12/22
08:05 am
scnx
SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA
High
Report
SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA
12/11
08:33 am
scnx
Scienture, BlinkRx announce strategic collaboration to expand access to Arbli [Yahoo! Finance]
Low
Report
Scienture, BlinkRx announce strategic collaboration to expand access to Arbli [Yahoo! Finance]
12/10
08:05 am
scnx
SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
Medium
Report
SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
12/9
05:08 pm
scnx
Scienture Holdings, Inc. (SCNX) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript [Seeking Alpha]
Low
Report
Scienture Holdings, Inc. (SCNX) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript [Seeking Alpha]
12/3
04:33 pm
scnx
Scienture (NASDAQ:SCNX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Scienture (NASDAQ:SCNX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
12/2
08:17 am
scnx
SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025 [Yahoo! Finance]
Low
Report
SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025 [Yahoo! Finance]
12/2
08:05 am
scnx
SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025
Low
Report
SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025
11/27
02:53 pm
scnx
Scienture (NASDAQ:SCNX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Scienture (NASDAQ:SCNX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/13
08:38 am
scnx
SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update [Yahoo! Finance]
11/13
08:05 am
scnx
SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update
Medium
Report
SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update
11/4
08:05 am
scnx
SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans
Low
Report
SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans
10/23
08:05 am
scnx
SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)
High
Report
SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)